Update on the Glenmark Symed dispute

/ By / Patent

(There is a correction to this post. One of our commentators has brought to our attention the Division Bench order available here, and that there was no remand to the Single Judge. The appeal has been admitted, the order of the Single Judge has been stayed and the matter is listed for arguments on April 6) SpicyIP had earlier reported on the injunction order awarded by the Delhi High Court against Glenmark’s manufacture of Symed’s linezolid. We now have more […]

Update on the Glenmark Symed dispute Read More »

Patent and Trademark Agent Examination Woes

/ By / Patent, Trademark

Is the end finally near? Thanks to a tip from one of our readers, Ms. Meera Sharma, it has come to our notice that it has been a preposterously long while since the last Patent and Trademark Agent Examinations respectively were last held, and applicants have been (quite understandably) been getting increasingly impatient at the inaction of the Government. THE TM AGENT EXAM The Trademark Agent Exam was last held in June 2010 – over four and a half years

Patent and Trademark Agent Examination Woes Read More »

SpicyIP Event: The Grand Masters 2015 – In-House Counsel Legal Best Practices Summit

/ By / Event, Sponsored

We’re happy to announce the The Grand Masters 2015! Please note, it will be held in three different cities on three different dates in February. And please also note while registering – SpicyIP readers are entitled to a 30% discount! Details of the summit are below: Have you been facing challenges as an In-House Counsel? Have you been able to build and lead successfully an In-House Team? Have you been able to strike a balance with the External Counsel? Do you have

SpicyIP Event: The Grand Masters 2015 – In-House Counsel Legal Best Practices Summit Read More »

SpicyIP Weekly Review (2nd February – 15th February, 2015)

/ By / Others

SpicyIP Highlight of the Week(s)! Over the last fortnight, we’ve seen a comprehensive takedown of the Global Intellectual Property Center’s International IP Index. Shamnad took off from where he left in his Republic Day post with an opinion piece questioning the blind faith placed on IP rankings, and at a more fundamental level, in the belief that stronger IP laws foster innovation. He concludes that India’s marginal improvement on the rankings seem to stem from the simple expedient of making the right noises at

SpicyIP Weekly Review (2nd February – 15th February, 2015) Read More »

SpicyIP Tidbit: ‘Singh & Singh’ & ‘Lall & Sethi’ to merge

/ By / Others

Yesterday, Bar and Bench reported that ‘Singh & Singh’ & ‘Lall & Sethi’, two prominent IP law firms in India, are merging to form ‘Singh & Singh Lall & Sethi’. ‘Singh & Singh’ & ‘Lall & Sethi’ are both leading law firms of the country having expertise in intellectual property law. Singh & Singh also has a very robust practice in telecommunication law. Singh & Singh Law Firm LLP was set up in 1997, by its founding partners, Mr. Maninder

SpicyIP Tidbit: ‘Singh & Singh’ & ‘Lall & Sethi’ to merge Read More »

Guest Post: Academics submits critical comments to DIPP on draft National IPR Policy by IP Think Tank

/ By / Copyright, Innovation, Others, Patent, Trademark

Raghul Sudheesh, a close friend of the blog, brings us some very important perspective on the draft IP policy from some of India’s top IP scholars, Prof N.S. Gopalakrishnan and Dr T.G. Agitha, both from Cochin University of Science and Technology (CUSAT). Prof N.S.Gopalakrishnan is internationally recognized as one of India’s foremost IPR experts, and has played a very influential role in policy making, international negotiations, and legislative drafting. They are very critical of the draft National IPR policy, pointing out several

Guest Post: Academics submits critical comments to DIPP on draft National IPR Policy by IP Think Tank Read More »

Delhi HC rules in favour of Gilead’s Sovaldi writ petition

/ By / Drug Regulation, Patent

In a judgement dated 30th January 2015, Justice Rajiv Shakdher of the Delhi High Court upheld the contentions of Gilead Sciences regarding their “blockbuster” Hepatitis C Virus drug, Sovaldi. We’ve previously covered the controversy surrounding Gilead’s pricing policies with respect to Sovaldi (see Rupali’s two-part post here and here), but the issues raised in the current writ petition are only tangentially connected to the price of the drug. We’d also carried the news of Gilead’s rejection at the IPO, and

Delhi HC rules in favour of Gilead’s Sovaldi writ petition Read More »

Patently Unjust: How India’s IP laws prevent the poor from living healthy lives

/ By / Others, Patent

Access to Medicines (“A2M”) has been an active space for clashes within IP scholarship over the last year, with several landmark developments taking place in quick succession. Big pharma’s attempts to secure its bottom line against India’s so-called ‘lax’ patent regime have been well documented. Ever since the Novartis ruling, the debate has firmly established its importance in the Indian context, with multinational corporations pushing for introspection in our IP laws. (For more on the manner in which pharma giants

Patently Unjust: How India’s IP laws prevent the poor from living healthy lives Read More »

DHC awards injunction against Glenmark’s manufacture of Symed’s linezolid

/ By / Patent

On 19th January, 2015, Hyderbad based Symed Labs won an interim injunction against Glenmark Pharmaceuticals’ manufacture of the drug ‘linezolid’, an anti-bacterial drug used for the treatment of pneumonia, among other infections, by way of the suit patented process. This order from the Delhi High Court makes Glenmark the fifth pharmaceutical company to be injuncted from selling the drug. Previous injuctions were awarded in two earlier suits against Optimus Pharma Pvt. Ltd., Alkem Laboratories Limited (Symed has now entered into

DHC awards injunction against Glenmark’s manufacture of Symed’s linezolid Read More »

SpicyIP Weekly Review (26th January to 1st February, 2015)

/ By / Others

Author’s note: In an earlier version of this post, I mistakenly represented the contents of the post ‘Dodgy IP Dogma’. This has been corrected now. SpicyIP Highlight of the Week! The SpicyIP Highlight of the Week was the first post of the week where Madhulika reported the clandestine settlement between Natco & BMS over ‘Entecavir’. Naturally, this is a worrying development; settlements between pharmaceutical companies are bad for competition in the market because they delay the entry of generic drugs

SpicyIP Weekly Review (26th January to 1st February, 2015) Read More »

Scroll to Top